维普期刊资源整合服务平台（V6.5）

79篇 您的检索式：作者名="Sprinzl"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.	Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler	2009	World Journal of Gastroenterology2009，15，4：	10
2	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B显示文摘	Jens M. Kittner Martin F. Sprinzl Annette Grambihler Arndt Weinmann J?rn M. Schattenberg Peter R. Galle Marcus Schuchmann	2012	Journal of Clinical Virology2012，，1：	2
3	Dendritic cells in precancerous lesions of the larynx显示文摘	Sprinzl GM Huss B Obrist P	2000	Laryngoscope2000，110，1：	1
4	Adding pegylated interferon to a current nucleos (t) ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B显示文摘	Kittner JM Sprinzl MF Grambihler A		0，，：	1
5	Local app- lication of granulocyte-macrophage colony stimu- lating factor(GM-CSF) for the treatment of oral mu- cositis 显示文摘	Sprinzl GM Galvan O de Vries A	2001	Eur J Cancer2001，37，16：	1
6	Complilation of tRNA sequences and sequences of tRNA genes显示文摘	Steegborn C Huebel F	1992	Nucl Acids Res1992，24，：	1
7	Facing the dawn of immunothera- py for hepatocellular carcinoma 显示文摘	SPRINZL MF GALLE PR	2013	J Hepatol2013，59，：	1
8	Electrochemical detection of microRNAs via gap hybridization assay 显示文摘	P6hlmann C Sprinzl M	2010	Anal Chem2010，82，11：	1
9	Compilation of tRNA sequences and sequences of tRNA genes显示文摘	Sprinzl M Vassilenko K S	2005	Nucleic Acids Research2005，33，：	1
10	Current trends in treating hear ing loss in elderly people: a review of the technology and treat ment options - a mini- review显示文摘	Sprinzl GM Riechelmann H	2010	Gerontology2010，56，351：	1
11	EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix in- teractions in primary human hepatocytes 显示文摘	PAULA B SPRINZL M ROSSET S	2009	Int J Cancer2009，124，：	1
12	Current trends in treatinghearing loss in elderly people : a review of the technologyand treatment options-a mini-review 显示文摘	Sprinzl G M Riechelmann H	2010	Gerontology2010，56，3：	1
13	Ni2+-binding RNA motifs with an asymmetric purine-rich internal loop and a G A base pair显示文摘	Hofmann H P Limmer S Hornung V Sprinzl M		0，，：	1
14	Continuous processing of recombinant proteins : integration of refolding and purification using simulated moving bed size-exclusion chromatography with buffer recycling显示文摘	Wellhoefer M Sprinzl W Hahn R	2013	J Chromatogr A2013，1319，：	1
15	Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice:crossing the species barrier显示文摘	Martin Franz Sprinzl Heike Oberwinkler Heinz Schaller	2001	J Virol2001，75，11：	1
16	Morphology of the human thyroglossal tract:a histologic and macroscopic study in infants and children 显示文摘	Sprinzl GM Koebke J Wimmers-Klick J	2000	Ann Otol Rhinol Laryngol2000，109，1：	1
17	Grading system for the selection of patients with congenital aural atresia for active middle ear implants显示文摘	Frenzel H Sprinzl G Widmann G	2013	Neuroradiology2013，55，7：	1
18	Chemistry of aminoacylation and peptide bond formation on the 3' terminus of tRNA显示文摘	Sprinzl M	2006	J Biosci2006，31，4：	1
19	Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier显示文摘	Sprinzl MF Oberwinkler H Sehaller H	2001	J Virol2001，75，11：	1
20	68 Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to 123 I-MIBG SPECT/CT显示文摘	Alexander Kroiss Barry Lynn Shulkin Christian Uprimny Andreas Frech Rudolf Wolfgang Gasser Christoph Url Kurt Gautsch Ruth Madleitner Bernhard Nilica Georg Mathias Sprinzl Guenther Gastl Gustav Fraedrich Irene Johanna Virgolini	2015	European Journal of Nuclear Medicine and Molecular Imaging2015，，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示